2016 American Transplant Congress » Poster Session D: Antibody Mediated Rejection: Session #2

6:00pm-7:00pm

Alloimmunity Through Non-HLA Epitopes in Kidney Transplantation.

R. Reindl-Schwaighofer,¹ A. Kainz,¹ B. Cole,² J. van Setten,² K. Jelencsics,¹ B. Keating,² R. Oberbauer.¹

6:00pm-7:00pm

Assessment of mRNA Gene Profiles in Plasma Exosome to Predict Risk for Antibody-Mediated Rejection (ABMR) of Renal Allografts.

H. Zhang,¹ J. Kahwaji,¹ P. Li,² S. Ge,¹ D. Thomas,¹ C. Nast,³ A. Vo,¹ M. Haas,³ S. Jordan,¹ M. Toyoda.¹

6:00pm-7:00pm

C1q Assays Are Not Associated with Clinical or Serologic Endpoints.

A. Gilbert,¹ M. Zaheer,¹ O. Timofeeva,² M. Awwad,² D. Li,² S. Rosen-Bronson,² B. Javaid,¹ M. Grafals,¹ J. Verbesey,¹ P. Abrams,¹ M. Cooper.¹

6:00pm-7:00pm

C1q Donor Specific Antibody Associates with Post Transplant Biopsy Findings in Highly Sensitized Kidney Transplant Recipients.

S. Kuppachi,¹ D. Holanda,² S. Gallegos,³ E. Field.^3,4

6:00pm-7:00pm

Detection of Endothelial Cell Specific Molecule-1 According to Allograft Status After Kidney Transplantation.

J.-W. Seo, S.-Y. Kim, Y.-G. Kim, Y.-H. Jeong, Y.-H. Lee, J.-Y. Moon, T.-W. Lee, C.-G. Ihm, S.-H. Lee.

6:00pm-7:00pm

Diffuse Extent of Peritubular Capillaritis in Late Antibody Mediated Rejection Is Associated with More Severe Chronic Allograft Damage.

Z. Kikić,¹ F. Eskandary,¹ H. Herkner,² R. Oberbauer,¹ G. Bond,¹ H. Regele,³ G. Böhmig,¹ N. Kozakowski.³

6:00pm-7:00pm

Digital Kidney Biopsy Evaluation: Quantification of Macrophage Prevalence in a Cross Sectional Study.

J. Schmitz,¹ A. Khalifa,¹ H. Haller,² H. Kreipe,¹ F. Feuerhake,¹ J. Bräsen.¹

6:00pm-7:00pm

Donor Specif Antibody (DSA) Kinetics in Patients with Antibody Mediated Rejection (AMR) Treated with Plasmapheresis and Bortezomib.

L. Requião-Moura,¹ M. Afonso,² A. Sakashita,³ M. Silva,¹ A. Matos,¹ A. Pacheco-Silva.¹

6:00pm-7:00pm

Elevation of Peripheral IL-6 in Kidney Transplant Recipients with Antibody Mediated Rejection.

N. Wilson, A. Djamali, R. Redfield.

6:00pm-7:00pm

Enhanced Natural Killer Responsiveness Is a Potent Cytotoxic Mechanism Associating to Kidney Allograft Dysfunction and Pathogenic Effects of Donor-Specific Antibodies (DSA).

P. Paul,^1,2 T. Legris,³ C. Picard,⁴ D. Todorova,^1,2 L. Lyonnet,¹ L. Daniel,⁵ B. Dussol,^3,6 V. Moal,³ H. Vacher Coponat,³ Y. Berland,³ F. Dignat-George,^1,2 S. Burtey.^2,3

6:00pm-7:00pm

Expansion of Anti-HLA Antibodies After Renal Transplantation and Prognosis in Those Which Fix C1q.

P. Ruiz-Esteban,¹ M. Gonzalez-Molina,¹ A. Caballero,² A. Torio,² M. Leon,³ E. Palma,¹ D. Burgos,¹ M. Cabello,¹ V. Lopez,¹ M. Rodriguez,⁴ D. Hernandez.¹

6:00pm-7:00pm

Factors Mediating Kidney Rejection in Patients of Simultaneous Liver-Kidney Transplants.

R. Dong, A. Tambur, L. Gallon, J. Levitsky.

6:00pm-7:00pm

Focal C4d Staining in Biopsies of Kidney Transplant Recipients Is Not Associated with Antibody Mediated Rejection and Does Not Correlate with Graft Survival.

R. Prashar, M. Goggins, L. Yessayan, A. Patel, M. Goggins.

6:00pm-7:00pm

Graft Survival in Sensitized and Non-Sensitized Patients: Role of the Combination of Donor-Specific Antibodies and Acute Rejection.

P. Souza,¹ A. Aguirre,¹ G. Bezerra,² H. Rodrigues,² F. Agena,¹ D. David,¹ F. de Paula,¹ E. David-Neto,¹ M. Castro.¹

6:00pm-7:00pm

HCV, Acute Rejection, and the New Direct-Acting Antivirals in Deceased Donor Kidney Transplant Recipients.

C. Liao, A. Massie, S. Bae, D. Segev.

6:00pm-7:00pm

Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).

A. Vo,¹ C. Boutsicaris,¹ X. Zhang,² N. Reinsmoen,² J. Choi,¹ S. Jordan.¹

6:00pm-7:00pm

Impact of C3d and C1q-Binding DSA Detected Long-Term After Kidney Transplantation.

M. Crespo,^1,2 D. Redondo,^1,2 C. Garcia,³ J. Gimeno,⁴ M. Perez,^1,2 M. Mir,¹ J. Hernandez,³ J. Yelamos,² A. Faura,^1,2 J. Pascual.^1,2

6:00pm-7:00pm

Kidney Transplant with Low Level DSA and Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates.

C. Schinstock, W. Cheungpasitporn, F. Cosio, D. Mitema, M. Gandhi, M. Prieto, P. Dean, M. Stegall.

6:00pm-7:00pm

Kidney Transplantation with Strong Preformed Donor-Specific Antibodies: Impact of C1q-Binding Ability.

J. Malheiro,¹ S. Tafulo,² S. Santos,¹ M. Costa,¹ L. Martins,¹ L. Dias,¹ A. Henriques.¹

6:00pm-7:00pm

Long Term Outcomes Following Antibody Mediated Rejection (AMR) in Renal Transplant Recipients.

R. Crew, S. Patel, H. Morris, M. Chiles, L. Ratner.

6:00pm-7:00pm

Outcomes of Second Kidney Transplantation Compared Primary Transplantation According to Donor Specific Antibody.

J. Lee,^1,2 K. Lee,¹ J. Lee,¹ S. Song,¹ J. Lee,¹ S.-K. Kwon,¹ D. Joo,^1,2 K. Huh,^1,2 M. Kim,^1,2 S. Kim,^1,2 Y. Kim.^1,2

6:00pm-7:00pm

Posttransplant AT1Rabs Precede De Novo HLA-DSA Development.

J. Arreola-Guerra,³ E. Cuevas,¹ E. Hernandez-Mendez,¹ M. Vilatoba,¹ A. Contreras,¹ J. Ramirez,¹ D. de Rongs,¹ J. Granados,¹ L. Morales-Buenrostro,² J. Alberu.¹

6:00pm-7:00pm

Predicting the Ability of Anti-HLA Antibodies to Activate Complement.

D. Bekbolsynov, C. Baum, B. Mierzejewska, A. Malebari, M. Rees, S. Stepkowski.

6:00pm-7:00pm

Presence of Highly Immunogenic Mismatch Eplets Is Associated with Development of Chronic Active Antibody-Mediated Rejection: A First Report from Japan.

D. Iwami, K. Morita, H. Sasaki, H. Higuchi, Y. Takada, N. Shinohara.

6:00pm-7:00pm

Role of Preformed IgM Donor Human Leucocyte Antigen (HLA) Specific Antibodies in HLA Incompatible Renal Transplantation.

A. Andreou, A. Babu, T. Barber, R. Higgins, D. Briggs, D. Mitchell, N. Khovanova, T. Shaikhina, S. Daga.

6:00pm-7:00pm

The Combined Effect of Acute Rejection and De Novo Donor-Specific Antibodies on Kidney Allograft Survival.

S. Davis, J. Gralla, A. Wiseman, J. Cooper.

6:00pm-7:00pm

The Early Outcomes of Bortezomib Therapy in Patients with Late Antibody Mediated Rejection in Renal Transplantation.

J. Choi, J. Jung, S. Shin, Y. Kim, D. Han.

6:00pm-7:00pm

The Effect of Tocilizmab Treatment (TCZ-Rx) on Total IgG and Anti-CMV-IgG Levels in HLA-Sensitized (HS) Kidney Transplant Patients.

B.-H. Shin, S. Ge, J. Choi, J. Kahwaji, A. Vo, A. Petrosyan, S. Jordan, M. Toyoda.

6:00pm-7:00pm

The Impact of Microvascular Inflammation (MVI) in Kidney Transplant Biopsies (KTxBx) Is Independent of Time Post-Transplant.

R. Gaston,¹ J. Grande,² R. Leduc,³ The DeKAF Study Group.

6:00pm-7:00pm

The Phenotypic Diversity of Late Silent Antibody-Mediated Rejection.

F. Eskandary,^1,2 J. Reeve,^1,3 H. Regele,⁴ L. Hidalgo,^1,3 D. Yoo,¹ N. Kozakowski,⁴ K. Famulski,¹ G. Böhmig,² P. Halloran.^1,5

6:00pm-7:00pm

The Prediction of Molecular ABMR by Anti-HLA Donor-Specific Antibody Properties.

F. Eskandary,^1,2 J. Reeve,^1,3 D. Yoo,¹ H. Regele,⁴ L. Hidalgo,^1,3 G. Böhmig,² P. Halloran.^1,5

6:00pm-7:00pm

Type of Sensitization Does Not Impact Kidney Graft Outcome in Weakly Sensitized Patients.

A. Morrison,¹ D. Sawinski,² M. Lim,² M. Levine,¹ M. Kamoun,³ P. Porrett.¹